Assignee
IMMUNIC AG
DE·7 granted patents·10 pending applications·3 citations·filing 2018–2024
Top patents by PatentIndex Score
17 records- 0190US11376232B2Vidofludimus for use in the treatment or prevention of viral diseasesIMMUNIC AG·Filed 2021·Granted Jul 5, 2022·2 cites·29 claims
- 0287US11877994B2Treatment of multiple sclerosis comprising DHODH inhibitorsIMMUNIC AG·Filed 2021·Granted Jan 23, 2024·1 cites·18 claims
- 0381US12433860B2Treatment of multiple sclerosis comprising DHODH inhibitorsIMMUNIC AG·Filed 2023·Granted Oct 7, 2025·0 cites·18 claims
- 0479US2025120931A1Treatment of multiple schlerosis comprising dhodh inhibitorsIMMUNIC AG·Filed 2024·Application pending·0 cites
- 0575US11877995B2Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseasesIMMUNIC AG·Filed 2022·Granted Jan 23, 2024·0 cites·34 claims
- 0673US2024100005A1Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune DiseasesIMMUNIC AG·Filed 2023·Application pending·0 cites
- 0767US12167994B2Vidofludimus for use in the treatment or prevention of viral diseasesIMMUNIC AG·Filed 2022·Granted Dec 17, 2024·0 cites·19 claims
- 0864US2025136542A1Calcium salt polymorphs as anti-inflammatory, immunodulatory and anti-proliferative agentsIMMUNIC AG·Filed 2024·Application pending·0 cites
- 0963US12037305B2Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agentsIMMUNIC AG·Filed 2019·Granted Jul 16, 2024·0 cites·16 claims
- 1063US2024335405A1Vidofludimus and related structures acting as nurr1 agonistsIMMUNIC AG·Filed 2024·Application pending·0 cites
- 1162US2025243190A1New deuterated rorgamma/rorgammat inverse agonistsIMMUNIC AG·Filed 2023·Application pending·0 cites
- 1260US2025066290A1Dhodh inhibitors containing a carboxylic acid bioisostereIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1360US2025032527A1Medical use of n4-hydroxy citicoline compoundsIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1458US2024368145A1Methods for treating cancerIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1557US2024199535A1Deuterated dhodh inhibitorsIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1654US2020360324A1Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune DiseasesIMMUNIC AG·Filed 2018·Application pending·0 cites
- 1741US11292788B2IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammationIMMUNIC AG·Filed 2018·Granted Apr 5, 2022·0 cites·11 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →